Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Significant Accounting Policies (Details)

v3.21.4
Nature of Business and Significant Accounting Policies (Details)
 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 24, 2021
USD ($)
Jun. 14, 2021
USD ($)
Oct. 31, 2018
USD ($)
Jun. 27, 2018
USD ($)
shares
Feb. 28, 2018
USD ($)
Dec. 04, 2017
USD ($)
Apr. 29, 2015
shares
Dec. 10, 2014
shares
Nov. 12, 2014
shares
Nov. 30, 2021
USD ($)
Nov. 30, 2020
USD ($)
Nov. 30, 2021
USD ($)
shares
Nov. 30, 2020
USD ($)
shares
May 31, 2021
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2021
USD ($)
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Equity Method Investment, Ownership Percentage                 55.60% 50.00%   50.00%        
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions (in Shares) | shares               6,250,000                
Stockholders' Equity Note, Stock Split, Conversion Ratio               0.625                
Debt Instrument, Face Amount                               $ 6,229,672
Asset Impairment Charges                           $ 2,498,706    
Financing Receivable, after Allowance for Credit Loss, Current   $ 3,000,000 $ 5,000,000                          
Proceeds from Collection of Notes Receivable                       $ 1,696,328 $ 1,385,951      
Cash and Cash Equivalents, at Carrying Value                   $ 1,284,070   1,284,070   1,665,263 $ 2,925,568  
Restricted Cash and Cash Equivalents                   250,000   250,000   0    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents                   1,534,070 $ 2,805,516 1,534,070 2,805,516      
Accounts Receivable, Credit Loss Expense (Reversal)                   129 0 129 5,992      
Goodwill       $ 25,742,899           557,896   557,896   557,896 557,896  
Advertising Expense                   341,872 311,707 788,538 443,739      
Research and Development Expense                   9,908 $ 5,385 $ 10,508 $ 12,392      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares                       75,430,955 88,474,321      
Goodwill, Impairment Loss                           25,185,003 25,185,003  
Principal [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Asset Impairment Charges                           2,497,884    
Accrued Interest [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Asset Impairment Charges                           822    
Reverse Merger with CLS Labs [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Stock Issued During Period, Shares, New Issues (in Shares) | shares             15,000,000                  
Oasis Acquisition [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Businesses, Gross         $ 6,200,000                      
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions         10.00%                      
Liabilities Assumed         $ 204,457                      
Oasis Acquisition [Member] | Deposit [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Businesses, Gross           $ 250,000                    
Oasis Acquisition [Member] | Additional Payments [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Businesses, Gross           $ 1,800,000                    
In Good Health [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Businesses, Gross     35,000,000                          
Business Combination, Consideration Transferred     47,500,000                          
Business Combination, Consideration Transferred, Liabilities Incurred     7,500,000                          
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned     5,000,000                          
Business Combination, Contingent Consideration, Liability     $ 2,500,000                          
Debt Instrument, Interest Rate, Stated Percentage     6.00%                          
Interest Rate, Default     15.00%                          
Financing Receivable, after Allowance for Credit Loss, Current                   $ 1,333,333   $ 1,333,333   0    
Proceeds from Collection of Notes Receivable                       1,696,328   $ 1,696,765 $ 1,425,000  
In Good Health [Member] | Principal [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Proceeds from Collection of Notes Receivable                       1,666,668        
In Good Health [Member] | Accrued Interest [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Proceeds from Collection of Notes Receivable                       29,660        
In Good Health [Member] | Due And Payable On Or Before June 21, 2021 [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Proceeds from Collection of Notes Receivable   500,000                            
In Good Health [Member] | Due And Payable On Or Before July 12, 2021 [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Proceeds from Collection of Notes Receivable   500,000                            
In Good Health [Member] | Due And Payable In12 Monthly Installments [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Proceeds from Collection of Notes Receivable   $ 2,000,000                            
Oasis LLCs [Member] | Oasis Acquisition [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Businesses, Gross       5,995,543                        
Debt Instrument, Face Amount       $ 4,000,000                        
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares) | shares       22,058,823                        
CLS Labs, Inc. [Member] | Shares of CLS Holdings USA, Inc. [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions (in Shares) | shares                 10,000,000              
Oasis LLCs [Member] | Oasis Acquisition [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       90.00%                        
Kealii Okamalu, LLC [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Equity Method Investment, Ownership Percentage 50.00%                              
Payments to Acquire Interest in Joint Venture                       100,000        
Kealii Okamalu, LLC [Member] | Investor [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Interest in Joint Venture                       $ 0        
Maximum [Member] | Kealii Okamalu, LLC [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Payments to Acquire Interest in Joint Venture $ 3,000,000                              
Warrant [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares                       6,625,868 54,835,145      
Equity Unit Purchase Agreements [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares                       3,041,290 7,676,974      
Convertible Debt Securities [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares                       65,693,797 25,454,696      
Stock Payable [Member]                                
Nature of Business and Significant Accounting Policies (Details) [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares                       70,000 507,506